Ask AI

Optimizing Integration of Bispecific Antibody Therapy to Improve Clinical Outcomes in Patients With Multiple Myeloma

Start Activity
Video
Video Start Activity
This activity is available for 1.00 CME/CE credit(s).

Released: September 08, 2026

Expiration: March 07, 2027

See Activity Collection

Step 1 of 5

1 Pre Assessment 2 Video 3 Post Assessment 4 Evaluation 5 Credit

In this on-demand webcast, experts examine the evolving role of bispecific antibodies in multiple myeloma, with emphasis on how emerging efficacy, sequencing, resistance, and safety data can inform individualized treatment decisions. Faculty review evidence for BCMA-directed and GPRC5D-directed bispecific therapies across relapsed/refractory and earlier-line settings, including results from MajesTEC, MagnetisMM, LINKER-MM, MonumenTAL, and RedirecTT studies, and discuss how prior BCMA exposure, CAR T-cell eligibility, target switching, disease characteristics, and patient-specific barriers may influence therapeutic selection and sequencing. Mechanisms of resistance to BCMA-directed and GPRC5D-directed therapy and practical management of treatment-related toxicities, including cytokine release syndrome, ICANS, infections, hypogammaglobulinemia, and GPRC5D-associated oral, skin, and nail effects, are also addressed. Finally, faculty outline strategies for step-up dosing, infection prophylaxis, caregiver education, monitoring, and outpatient care infrastructure, providing learners with a practical framework for integrating bispecific antibodies safely and effectively into contemporary multiple myeloma practice.

Carol Ann Huff
Carol Ann Huff, MD
Sagar Lonial
Sagar Lonial, MD, FACP, FASCO
BsAb Integration for MM

Pre Assessment

Assess your current knowledge and clinical approach before beginning your video.
Begin Your Video
1.

How many people with multiple myeloma do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

You are counseling a patient with relapsed multiple myeloma who will receive treatment with a bispecific antibody. Their caregiver asks you about differences among the available therapies. You tell them that 3 of the approved bispecific antibodies for R/R MM are administered subcutaneously and one is administered intravenously.

Which drug do you tell them is administered intravenously?

4.

A 78-yr-old man with relapsed MM was initially diagnosed with MM in 2015. He has now had 4 prior lines of therapy, including VRD followed by SCT and lenalidomide maintenance (5 yr), followed by DaraKd (3 yr), then PomCyDex (1 yr) followed by ciltacabtagene (2 yr ago). His PET CT shows multiple sites of extramedullary disease.

What would you recommend next? 

5.

A 75-yr-old female patient was diagnosed with MM in 2020 and received DaraVRd followed by SCT and lenalidomide maintenance and is progressing 5 yr into maintenance therapy. 

She lives alone and does not have caregiver support, nor does she want to proceed to CAR T-cell therapy.

What would you recommend as second-line therapy for this patient? 

6.

A 74-yr-old patient with triple-class refractory MM is admitted for inpatient monitoring after initiating a BCMA-targeted BsAb. Seventeen hr after his first full dose, he develops grade 2 CRS with hypotension unresponsive to fluid resuscitation.

In addition to holding BsAb therapy, what is the most appropriate next step?

7.

You plan to begin administering bispecific T-cell engagers for MM including step-up dosing in your ambulatory clinic.

To ensure patient safety, having plans for all EXCEPT which of the following is essential?

Begin Your Video